Ionis Pharmaceuticals' Q3 Net Loss Narrows as Revenue Increases; 2026 Revenue Guidance Maintained

07:26 AM EST, 11/09/2026 (MT Newswires) -- Ionis Pharmaceuticals (IONS) reported Monday a Q3 net loss of $0.66 per diluted share, narrowing from the $0.80 loss per share a year earlier. Analysts polled by FactSet expected a loss of $1.23 per share. Revenue for the quarter ended Sept. 30 was $243 million, compared with $157 million a year earlier. Analysts expected $178.2 million. The company reiterated its 2026 revenue outlook of $875 million to $900 million. Analysts expect $922.2 million. Shares of Ionis Pharmaceuticals were down more than 9% premarket Monday.